The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Case study: Spesolimab for the treatment of GPP flare
Generalized pustular psoriasis (GPP) results in acute, widespread onset of erythematous plaques with pustules, and can be difficult-to-treat.1 Spesolimab, an interleukin-36 inhibitor, has previously shown efficacy in treating GPP flares in the Effisayil-1 trial.1 Here, we summarize a case study by Brigenti et al.1 published in Sage Open Medical Case Reports on the treatment of GPP flare with spesolimab.
Patient history1
-
A 48-year-old patient, with a long history of psoriasis experienced a GPP flare after previously having stable disease, controlled by secukinumab for 6 years (Figure 1).
Figure 1. Patient history*
GPP, generalized pustular psoriasis.
*Data from Brigenti, et al.1 Created with BioRender.com.
Flare and treatment1
-
In October 2022, the patient experienced a severe GPP flare (Figure 2). In addition, she experienced fatigue, malaise, fever, and agitation.
-
To treat the flare, two doses of spesolimab 900 mg were administered intravenously (Figure 3). After 5 months of follow-up, the patient achieved complete clinical remission.
Figure 2. Characteristics of GPP flare*
DLQI, Dermatology Life Quality Index; GPPASI, Generalized Pustular Psoriasis Area and Severity Index; GPPGA, Generalized Pustular Psoriasis Physician’s Global Assessment.
*Data from Brigenti, et al.1 Created with BioRender.com.
Figure 3. Treatment timeline*
GPP, generalized pustular psoriasis.
*Data from Brigenti, et al.1 Created with BioRender.com.
After GPP reoccurrence at 5 months, treatment with secukinumab 300 mg led to clinical remission (measured at 8 months)
-
Generalized Pustular Psoriasis Physician’s Global Assessment score: 0
-
Generalized Pustular Psoriasis Area and Severity Index score: 0
-
Dermatology Life Quality Index: 1
|
Key learnings |
|
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content